Daewoong Pharmaceutical CO.,LTD. established in 1945, is a global pharmaceutical company based in South Korea, focused on the development, manufacturing, and commercialization of innovative pharmaceutical products. With a mission to enhance the quality of life, the company specializes in treatments for rare and intractable diseases. Daewoong's diverse portfolio includes novel drugs, biologics, new products, and C&D, all supported by strong in-house R&D and advanced manufacturing capabilities. Notable achievements include the development of Fexuprazan for GERD and Enavogliflozin for Type 2 diabetes. Currently, Daewoong is advancing its First-in-Class Oral Anti-Fibrotic Agent, Bersiporocin, for Idiopathic Pulmonary Fibrosis, which has received orphan drug and Fast Track designations from the U.S. FDA. Daewoong aims to complete the Phase 2 study by 2025.